In addition, β‐TrCP promotes lymphocytic leukaemia cell proliferation through concomitant activation of NF‐κB and β‐catenin/TCF signalling pathways, suggesting that β‐TrCP–NF‐κB–β‐catenin pathway could be considered a potential target for cancer therapy.188. The gene discussed is BTRC; the disease is cancer.